EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy

Axel S Merseburger iD, Neeraj Agarwal, Anders Bjartell iD, Hirotsugu Uemura iD, Alvaro Juarez Soto, Amitabha Bhaumik, Jürgen Böhm, Nguyen Tran, Nils Krochmann, Mehregan Nematian-Samani, Suneel D Mundle iD, Sabine D Brookman-May und 4 weitere

BJU International · 2024

DOI: 10.1111/bju.16449 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, 2024. Verfasst von Axel S Merseburger und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Thiohydantoins, Prostate-Specific Antigen, Androgen Antagonists, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the association between achievement of prostate‐specific antigen (PSA) levels ≤0.2 ng/mL (henceforth ‘ultralow’) and clinical outcomes in patients in the ‘Targeted Investigational Treatment Analysis of Novel Anti‐androgen’ (TITAN) study (ClinicalTrials.gov Identifier NCT02489318) with metastatic castration‐sensitive prostate cancer (mCSPC). Patients and Methods Patients in the TITAN study with mCSPC were randomised to 240 mg/day apalutamide ( n = 525) or placebo ( n = 527) plus androgen‐deprivation therapy. This post hoc analysis assessed the achievement of a PSA level of 0.2–>0.02 ng/mL (‘ultralow one’ [UL1]) and ≤0.02 ng/mL (‘ultralow two’ [UL2]) vs >0.2 ng/mL with apalutamide treatment and its association with radiographic progression‐free survival (rPFS), overall survival (OS), time to castration‐resistant PC (TTCRPC), and time to PSA progression (TTPP). The landmark analysis and Kaplan–Meier methods were used.

Results

By 3 months, more patients achieved UL1 and UL2 with apalutamide (38% and 23%) vs placebo (15% and 5%). In the apalutamide‐treated patients, UL2 vs PSA >0.2 ng/mL at landmark 3 months was associated with significantly longer rPFS (hazard ratio [HR] 0.28, 95% confidence interval [CI] 0.14–0.54), OS (HR 0.24, 95% CI 0.13–0.43), TTCRPC (HR 0.2, 95% CI 0.11–0.38), and TTPP (HR 0.11, 95% CI 0.04–0.27; nominal P values all 0.2 ng/mL anytime (HR 0.12, 95% CI 0.06–0.22; P < 0.001) in apalutamide‐treated patients.

Conclusions

In this post hoc analysis of TITAN, patients with the deepest PSA decline derived the greatest benefit. These results extend our findings of apalutamide efficacy in the overall TITAN population, underscoring the clinical value of PSA kinetics as a marker for treatment efficacy. Patient Summary Patients with metastatic prostate cancer that is sensitive to ongoing hormonal treatment benefited significantly from the addition of apalutamide compared with placebo. Those who achieved rapid and deep PSA reduction had the greatest survival benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiohydantoinsProstate-Specific AntigenAndrogen AntagonistsProstatic Neoplasms, Castration-ResistantHumansMaleAgedMiddle AgedTreatment OutcomeDouble-Blind MethodProgression-Free Survival

Stichwörter der Autor:innen

Androgen‐deprivation therapyandrogen receptor inhibitionhormone treatmentmetastatic castration‐sensitive prostate cancerprostate‐specific antigen

Substanzen

apalutamideThiohydantoinsProstate-Specific AntigenAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
  • Department of Genitourinary Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Department of Urological Cancer, Skåne University Hospital, Lund University, Malmö, Sweden.
  • Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Department of Urology, Hospital Universitario de Jerez de la Frontera, Cadiz, Spain.
  • Janssen Research and Development, Titusville, NJ, USA.

ORCID-Profile: Axel S Merseburger, Anders Bjartell, Hirotsugu Uemura, Suneel D Mundle

Förderung

  • Janssen Research and Development

Zitieren

APA

Merseburger, A. S., Agarwal, N., Bjartell, A., Uemura, H., Soto, A. J., Bhaumik, A., Böhm, J., Tran, N., Krochmann, N., Nematian-Samani, M., Mundle, S. D., Brookman-May, S. D., Lopez-Gitlitz, A., McCarthy, S. A., Chi, K., & Chowdhury, S. (2024). Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy. BJU International. https://doi.org/10.1111/bju.16449

Vancouver

Merseburger AS, Agarwal N, Bjartell A, Uemura H, Soto AJ, Bhaumik A, et al. Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy. BJU International. 2024. doi:10.1111/bju.16449

BibTeX
@article{Merseburger2024,
  author = {Merseburger, Axel S and Agarwal, Neeraj and Bjartell, Anders and Uemura, Hirotsugu and Soto, Alvaro Juarez and Bhaumik, Amitabha and Böhm, Jürgen and Tran, Nguyen and Krochmann, Nils and Nematian-Samani, Mehregan and Mundle, Suneel D and Brookman-May, Sabine D and Lopez-Gitlitz, Angela and McCarthy, Sharon A and Chi, Kim and Chowdhury, Simon},
  title = {Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16449}
}
Kostenlos starten →